For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Ixekizumab - Psoriatic arthritis
PAD Profile : Ixekizumab - Psoriatic arthritis
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Adalimumab
- Ciclosporin
- Etanercept
- Golimumab
- Infliximab
- Sulfasalazine
- Ustekinumab (Psoriasis)
- Certolizumab pegol
- Apremilast
- Secukinumab
- Tofacitinib
- Methotrexate
- Guselkumab (Psoriasis)
- Upadacitinib
- Risankizumab
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Psoriatic arthritis high cost immunomodulator treatment pathway.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriatic Arthritis High Cost immunomodulator Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
The Prescribing Clinical Network (PCN) recommends ixekizumab (Taltz®) as a treatment option in active Psoriatic Arthritis after inadequate response to disease-modifying antirheumatic drugs (DMARDs) in line with NICE TA537 (August 2018)
Ixekizumab for this indication will be considered as RED on the traffic light system and treatment should be initiated and continued by specialist rheumatology clinicians.